Incidence and predictors of relapse during continuation treatment of major depression with SSRI, interpersonal psychotherapy, or their combination
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Despite the availability of many effective treatments, patients with major depression remain at risk for relapse following remission of a depressive episode. The aims of this report are to estimate the relapse rates associated with the acute treatment strategies employed in this study and to investigate demographic and clinical predictors of relapse. METHODS: The study sample includes 225 patients who entered the 6-month continuation treatment phase after remitting from an acute depressive episode. Treatment during the acute phase was interpersonal psychotherapy, SSRI (escitalopram), or the combination of the two when monotherapy did not lead to response. Relapse was defined by a Hamilton Depression Rating Scale score ≥15, confirmed by the diagnosis of major depression. The probability of relapsing was modeled using logistic regression. Three separate models were fit with subgroups of covariates. RESULTS: Of the 225 patients, 29 (12.9%) relapsed and 28 (12.4%) discontinued the protocol prematurely. The proportion of patients who relapsed among the group requiring combination treatment to achieve remission was three times as high as among patients who had remitted with monotherapy. In the final logistic regression model, older age, higher baseline HDRS scores, last month (residual) depressive mood spectrum factor score, and requiring combination treatment to achieve remission were each associated with an increased likelihood of relapse. CONCLUSIONS: Our results suggest that greater initial depression severity, greater difficulty in stabilizing symptoms, and presence of residual mood spectrum symptoms once remission is achieved are predictive of relapse. Risk of relapse is more likely as age increases, partly because aging confers lower resilience.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Self-citationFrank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959 · cited 3×
“[10] Long-term antidepressant pharmacotherapy at the full acute dose for 4–9 months after response or remission is considered the first-line treatment for preventing relapse.[8,9] Several studies demonstrated that prolonged treatment with SSRI pharmacotherapy reduces the relapse risk relative to placebo.”
BackgroundMethodInfluentialSelf-citationJudd, L. L., Akiskal, H. S., Maser, J. D., Zeller, P. J., Endicott, J., Coryell, W., Paulus, M. P., Kunovac, J. L., Leon, A. C., Mueller, T. I., et al. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00138-4 · Cited by 590
Vittengl, J. R., Clark, L. A., Dunn, T. W., & Jarrett, R. B. (2007) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.75.3.475 · Cited by 551
Treatment and prevention of depression
Hollon, S. D., Thase, M. E., & Markowitz, J. C. (2002) · Psychological Science in the Public Interest · doi:10.1111/1529-1006.00008 · Cited by 511
Maintenance Treatment of Major Depression in Old Age
Reynolds, C. F., Dew, M. A., Pollock, B. G., Mulsant, B. H., Frank, E., Miller, M. D., Houck, P. R., Mazumdar, S., Butters, M. A., Stack, J. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052619 · Cited by 476 · cited 1×
“[21–25] The Frank et al.”
Self-citationResidual symptoms in depressed patients who respond acutely to fluoxetine
Nierenberg, A. A., Keefe, B. R., Leslie, V. C., Alpert, J. E., Pava, J. A., Worthington, J. J., Rosenbaum, J. F., & Fava, M. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0403 · Cited by 470 · cited 1×
“[2–7] According to conventions developed in the pharmacotherapy literature,[8] a relapse is defined as an episode of MDD (major depressive disorder) that occurs within 6 months after either response or remission.”
MethodFive-Year Outcome for Maintenance Therapies in Recurrent Depression
Kupfer, D. J. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820100013002 · Cited by 370
Self-citationCognitive Behavioral Therapy for Mood Disorders: Efficacy, Moderators and Mediators
Driessen, E., & Hollon, S. D. (2010) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2010.04.005 · Cited by 291 · cited 1×
“It remains unclear whether this effect is specific to CBT, because other psychotherapies have only rarely been tested against medication withdrawal.[18] The studies carried out in the last two decades that examined the effects of the combination of interpersonal psychotherapy (IPT)[19,20] and pharmacotherapy, for prev…”
BackgroundA review of empirically supported psychological therapies for mood disorders in adults
Hollon, S. D., & Ponniah, K. (2010) · Depression and Anxiety · doi:10.1002/da.20741 · Cited by 267 · cited 1×
“Treatment provided after the end of such a 6-month interval is referred to as maintenance treatment.[10] Long-term antidepressant pharmacotherapy at the full acute dose for 4–9 months after response or remission is considered the first-line treatment for preventing relapse.”
BackgroundSubclinical symptoms in mood disorders: pathophysiological and therapeutic implications
FAVA, G. A. (1999) · Psychological Medicine · doi:10.1017/s0033291798007429 · Cited by 258
(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.8.1046 · Cited by 252 · cited 1×
“[2–7] According to conventions developed in the pharmacotherapy literature,[8] a relapse is defined as an episode of MDD (major depressive disorder) that occurs within 6 months after either response or remission.”
MethodKaymaz, N., van Os, J., Loonen, A. J. M., & Nolan, W. A. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0910 · Cited by 135
Escitalopram continuation treatment prevents relapse of depressive episodes
Rapaport, M. H., Bose, A., & Zheng, H. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0107 · Cited by 121
Predictors of Relapse in a Prospective Study of Fluoxetine Treatment of Major Depression
McGrath, P. J., Stewart, J. W., Quitkin, F. M., Chen, Y., Alpert, J. E., Nierenberg, A. A., Fava, M., Cheng, J., & Petkova, E. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1542 · Cited by 111
Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse
Iovieno, N., van Nieuwenhuizen, A., Clain, A., Baer, L., & Nierenberg, A. A. (2011) · Depression and Anxiety · doi:10.1002/da.20768 · Cited by 98
Escitalopram: A Review of its Use in the Management of Major Depressive Disorder in Adults
Garnock-Jones, K. P., & McCormack, P. L. (2010) · CNS Drugs · doi:10.2165/11204760-000000000-00000 · Cited by 66
Yang, H., Chuzi, S., Sinicropi-Yao, L., Johnson, D., Chen, Y., Clain, A., Baer, L., McGrath, P. J., Stewart, J. W., Fava, M., et al. (2010) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-009-0031-3 · Cited by 42
Oestergaard, S., & Møldrup, C. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.08.014 · Cited by 38 · cited 1×
“A recent meta-analysis indicated that patients receiving combined treatment of antidepressants and CBT during the acute and the continuation phase are at lower risk of relapses, compared with patients receiving pharmacotherapy alone.[16] There is also evidence that CBT has an effect that lasts beyond the end of active…”
Result
Cited by
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“These include substance use, the experience of significant life events or ongoing psychosocial stressors, the presence of comorbid medical or psychiatric illnesses and the characteristics of the depressive illness itself (McGrath et al., 2006; Rucci et al., 2011).”
BackgroundRenoir, T. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00045 · Cited by 107
“…effects arising from long-term antidepressant treatment, as well as issues of relapse, and recurrence following remission of a depressive episode (Rucci et al., 2011; Rush et al., 2012), the existence of a SSRI discontinuation syndrome (also known as SSRI withdrawal syndrome) has been suggested…”
BackgroundInfluentialWojnarowski, C., Firth, N., Finegan, M., & Delgadillo, J. (2019) · Behavioural and Cognitive Psychotherapy · doi:10.1017/s1352465819000080 · Cited by 108
Saragoussi, D., Touya, M., Haro, J. M., Jönsson, B., Knapp, M., Botrel, B., Florea, I., Loft, H., & Rive, B. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s136343 · Cited by 63
Metadata
- Authors
- Rucci, P., Frank, E., Calugi, S., Miniati, M., Benvenuti, A., Wallace, M., Fagiolini, A., Maggi, L., Kupfer, D. J., & Cassano, G. B.
- Venue
- Depression and Anxiety
- Publisher
- Hindawi Limited
- Published
- 2011-09-02
- Volume
- 28
- Issue
- 11
- Pages
- 955-962
- ISSN
- 1091-4269 (ISSN-L)
- OpenAlex
- W2076537855
- Cited by
- 33
- References
- 19
- FWCI
- 2.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.